A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: February 10, 2012
Last updated: July 1, 2015
Last verified: July 2015

This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with systemic sclerosis. Patients will be randomized to receive either RoActemra/Actemra 162 mg subcutaneously weekly or placebo for 48 weeks. From Week 49 to Week 96, all patients will receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on study treatment is 96 weeks.

Condition Intervention Phase
Sclerosis, Systemic
Drug: Placebo
Drug: tocilizumab [RoActemra/Actemra]
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change in modified Rodnan skin score (mRSS) [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in physical function, assessed by Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) [ Designated as safety issue: No ]
  • Change in joint tenderness, assessed by 28 tender joint count (TJC), in patients with joint involvement at baseline [ Designated as safety issue: No ]
  • Pharmacokinetics: Area under the concentration--time curve (AUC) [ Designated as safety issue: No ]
  • Pharmacodynamics: sIL-6R/IL-6 levels [ Designated as safety issue: No ]
  • Immunogenicity: anti-tocilizumab antibody level [ Designated as safety issue: No ]

Enrollment: 87
Study Start Date: March 2012
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Subcutaneously weekly, Weeks 1-48
Drug: tocilizumab [RoActemra/Actemra]
162 mg subcutaneously weekly, Week 49-96
Experimental: Tocilizumab Drug: tocilizumab [RoActemra/Actemra]
162 mg subcutaneously weekly, Weeks 1-48
Drug: tocilizumab [RoActemra/Actemra]
162 mg subcutaneously weekly, Week 49-96


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Systemic sclerosis, as defined by American College of Rheumatology (1980) criteria
  • Disease duration of </= 60 months (defined as time from first non-Raynaud phenomenon manifestation)
  • >/= 15 and </= 40 mRSS units at screening
  • Active disease, as defined by protocol
  • Uninvolved skin at injection sites
  • Negative pregnancy test for a female subject of childbearing potential

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to and/or during study enrollment
  • Rheumatic autoimmune disease other than systemic sclerosis
  • Skin thickening (scleroderma) limited to areas distal to the elbows or knees at screening
  • Previous treatment with tocilizumab
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Severe cardiopulmonary disease
  • Known active current or history of recurrent infections
  • Use of any investigational, biologic, or immunosuppressive therapies including intra-articular or parenteral corticosteroids prior to study enrollment as specified in the protocol
  • As specified in the protocol, any current or past medical condition or medical history involving but not limited to the nervous, renal, pulmonary, endocrine, and gastrointestinal organ systems determined by the Principal Investigator to pose a significant safety risk to any subject while participating in the study
  • Primary or secondary immunodeficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01532869

  Hide Study Locations
United States, California
Los Angeles, California, United States, 90025
San Diego, California, United States, 44122
Stanford, California, United States, 94305-5317
United States, Connecticut
Farmington, Connecticut, United States, 06030
United States, District of Columbia
Washington, District of Columbia, United States, 20007
United States, Illinois
Chicago, Illinois, United States, 60611
United States, Maryland
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Boston, Massachusetts, United States, 02118
United States, Michigan
Ann Arbor, Michigan, United States, 48109-0934
United States, New Jersey
New Brunswick, New Jersey, United States, 08903
United States, New York
Lake Success, New York, United States, 11042
New York, New York, United States, 10021
United States, Ohio
Cleveland, Ohio, United States, 44195
Toledo, Ohio, United States, 43614
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19131
Pittsburgh, Pennsylvania, United States, 15261
United States, South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Houston, Texas, United States, 77030
United States, Utah
Salt Lake City, Utah, United States, 84132
United States, Washington
Seattle, Washington, United States, 98104
Canada, Ontario
London, Ontario, Canada, N6A 4V2
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
Montreal, Quebec, Canada, H3T 1E2
Bordeaux, France, 33075
Caen, France, 14033
Lille, France, 59037
Paris, France, 75679
Strasbourg, France, 67091
Toulouse, France, 31000
Bad Nauheim, Germany, 61231
Baden-Baden, Germany, 76530
Berlin, Germany, 10177
Bochum, Germany, 44791
Dresden, Germany, 01067
Erlangen, Germany, 91054
Frankfurt, Germany, 60528
Hamburg, Germany, 22763
Köln, Germany, 50937
Tübingen, Germany, 72076
Ulm, Germany, 89081
United Kingdom
Cannock, United Kingdom, WS11 5XY
Dundee, United Kingdom, DD1 9SY
Edinburgh, United Kingdom, EX4 2HU
Leeds, United Kingdom, LS7 4SA
Liverpool, United Kingdom, L9 7AL
London, United Kingdom, NW3 2QG
Middlesborough, United Kingdom, TS4 3BW
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Romford, United Kingdom, RM7 0AG
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01532869     History of Changes
Other Study ID Numbers: WA27788, 2011-001460-22
Study First Received: February 10, 2012
Last Updated: July 1, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Scleroderma, Diffuse
Scleroderma, Systemic
Connective Tissue Diseases
Pathologic Processes
Skin Diseases

ClinicalTrials.gov processed this record on October 09, 2015